CDX2—a biomarker associated with tumor differentiation—also holds significant clinical relevance in CRC management; it is typically expressed in healthy colon cells but is often absent in poorly differentiated CRCs, correlating with aggressive disease and poorer outcomes. The gene discussed is CDX2; the disease is colorectal carcinoma.